Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Clinical trial NCT01591863 · COMPLETED
Trial details
- NCT number
- NCT01591863
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-06-15
- Primary completion
- 2014-03-07
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.